Niche Preclinical Focus Target small and mid-size pharma where Gerson offers end-to-end preclinical development strategies and issue resolution, presenting a clear opportunity to expand services into larger therapeutic programs.

Partnership Readiness Position Gerson as a bridge to larger partners by highlighting expertise in preparing programs for due diligence and discussions with big CROs or sponsors, aligning with potential buyers for later-stage development.

Agile Engagement Emphasize lean operating model and specialized capabilities suitable for SMBs, enabling fast onboarding and flexible engagement terms that resonate with emerging biotech and niche manufacturers.

Budget-Friendly Entry Leverage the current revenue range and small team size to tailor scalable service packages or retainer models that fit mid-size companies' budget constraints while enabling expansion into later-stage work.

Competitive Positioning Differentiate from large CROs by focusing on personalized, scientifically rigorous problem solving during preclinical development, offering rapid issue resolution and targeted strategy sessions.